MA27500A1 - Prevention et traitement de la maladie d'alzheimer - Google Patents
Prevention et traitement de la maladie d'alzheimerInfo
- Publication number
- MA27500A1 MA27500A1 MA28329A MA28329A MA27500A1 MA 27500 A1 MA27500 A1 MA 27500A1 MA 28329 A MA28329 A MA 28329A MA 28329 A MA28329 A MA 28329A MA 27500 A1 MA27500 A1 MA 27500A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- alzheimer
- disease
- prevention
- treatment
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 abstract 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 229940121773 Secretase inhibitor Drugs 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215722A FR2848452B1 (fr) | 2002-12-12 | 2002-12-12 | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27500A1 true MA27500A1 (fr) | 2005-08-01 |
Family
ID=32338722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28329A MA27500A1 (fr) | 2002-12-12 | 2005-06-10 | Prevention et traitement de la maladie d'alzheimer |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1572174A1 (https=) |
| JP (1) | JP2006514063A (https=) |
| KR (1) | KR20050084250A (https=) |
| CN (1) | CN1726016A (https=) |
| AR (1) | AR042354A1 (https=) |
| AU (1) | AU2003296802A1 (https=) |
| BR (1) | BR0317280A (https=) |
| CA (1) | CA2507945A1 (https=) |
| CO (1) | CO5700712A2 (https=) |
| FR (1) | FR2848452B1 (https=) |
| HR (1) | HRP20050534A2 (https=) |
| MA (1) | MA27500A1 (https=) |
| MX (1) | MXPA05005556A (https=) |
| NO (1) | NO20053341L (https=) |
| NZ (1) | NZ540496A (https=) |
| PE (1) | PE20040770A1 (https=) |
| PL (1) | PL377110A1 (https=) |
| RS (1) | RS20050420A (https=) |
| RU (1) | RU2005121909A (https=) |
| TW (1) | TW200503707A (https=) |
| WO (1) | WO2004062652A1 (https=) |
| ZA (1) | ZA200504656B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| AU2004290499C1 (en) | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| CA2554809C (en) | 2004-02-05 | 2014-04-29 | Probiodrug Ag | Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase |
| JP2008518955A (ja) | 2004-11-02 | 2008-06-05 | ノースウェスタン ユニバーシティ | ピリダジン化合物および方法 |
| US8158627B2 (en) | 2006-04-28 | 2012-04-17 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| KR101441725B1 (ko) * | 2007-05-22 | 2014-09-18 | 오츠카 세이야쿠 가부시키가이샤 | 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제 |
| US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| AU2012328526B2 (en) * | 2011-10-28 | 2017-05-25 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2040996A1 (en) * | 1990-05-02 | 1991-11-03 | Robert L. Albright | Composition and method for controlling cholesterol |
| EP0572560B1 (en) * | 1991-02-22 | 2003-01-29 | SHAPIRO, Howard, K. | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| CA2258744A1 (en) * | 1996-06-27 | 1997-12-31 | G.D. Searle And Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| ATE320803T1 (de) * | 1998-01-28 | 2006-04-15 | Warner Lambert Co | Verfahren zur behandlung von alzheimerschen krankheit |
| US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19825804C2 (de) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19845405C2 (de) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
| AU2001233299A1 (en) * | 2000-02-04 | 2001-08-14 | Esperion Therapeutics Inc. | Methods for treating alzheimer's disease |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
-
2002
- 2002-12-12 FR FR0215722A patent/FR2848452B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-10 WO PCT/FR2003/003654 patent/WO2004062652A1/fr not_active Ceased
- 2003-12-10 PL PL377110A patent/PL377110A1/pl not_active Application Discontinuation
- 2003-12-10 RS YUP-2005/0420A patent/RS20050420A/sr unknown
- 2003-12-10 JP JP2004566119A patent/JP2006514063A/ja not_active Abandoned
- 2003-12-10 EP EP03815109A patent/EP1572174A1/fr not_active Withdrawn
- 2003-12-10 AU AU2003296802A patent/AU2003296802A1/en not_active Abandoned
- 2003-12-10 CN CNA2003801059727A patent/CN1726016A/zh active Pending
- 2003-12-10 PE PE2003001247A patent/PE20040770A1/es not_active Application Discontinuation
- 2003-12-10 NZ NZ540496A patent/NZ540496A/en unknown
- 2003-12-10 KR KR1020057010595A patent/KR20050084250A/ko not_active Withdrawn
- 2003-12-10 RU RU2005121909/15A patent/RU2005121909A/ru not_active Application Discontinuation
- 2003-12-10 CA CA002507945A patent/CA2507945A1/fr not_active Abandoned
- 2003-12-10 BR BR0317280-5A patent/BR0317280A/pt not_active IP Right Cessation
- 2003-12-10 AR ARP030104540A patent/AR042354A1/es not_active Application Discontinuation
- 2003-12-10 HR HR20050534A patent/HRP20050534A2/xx not_active Application Discontinuation
- 2003-12-10 MX MXPA05005556A patent/MXPA05005556A/es not_active Application Discontinuation
- 2003-12-11 TW TW092134949A patent/TW200503707A/zh unknown
-
2005
- 2005-06-07 ZA ZA200504656A patent/ZA200504656B/en unknown
- 2005-06-09 CO CO05056010A patent/CO5700712A2/es not_active Application Discontinuation
- 2005-06-10 MA MA28329A patent/MA27500A1/fr unknown
- 2005-07-08 NO NO20053341A patent/NO20053341L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05005556A (es) | 2005-07-26 |
| BR0317280A (pt) | 2005-11-08 |
| PL377110A1 (pl) | 2006-01-23 |
| PE20040770A1 (es) | 2004-12-10 |
| FR2848452B1 (fr) | 2007-04-06 |
| CN1726016A (zh) | 2006-01-25 |
| FR2848452A1 (fr) | 2004-06-18 |
| WO2004062652A1 (fr) | 2004-07-29 |
| EP1572174A1 (fr) | 2005-09-14 |
| RU2005121909A (ru) | 2006-01-20 |
| RS20050420A (sr) | 2007-04-10 |
| ZA200504656B (en) | 2006-08-30 |
| JP2006514063A (ja) | 2006-04-27 |
| AR042354A1 (es) | 2005-06-15 |
| AU2003296802A1 (en) | 2004-08-10 |
| KR20050084250A (ko) | 2005-08-26 |
| CO5700712A2 (es) | 2006-11-30 |
| HRP20050534A2 (en) | 2006-11-30 |
| NO20053341D0 (no) | 2005-07-08 |
| NO20053341L (no) | 2005-09-07 |
| NZ540496A (en) | 2008-04-30 |
| TW200503707A (en) | 2005-02-01 |
| CA2507945A1 (fr) | 2004-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN01125A1 (fr) | Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine | |
| GB0223040D0 (en) | Therapeutic compounds | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
| EP1604664A4 (en) | MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE | |
| WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TNSN98155A1 (fr) | Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation | |
| EP1910829A4 (en) | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGEN DISEASES | |
| EP1899486A4 (en) | METHOD FOR IDENTIFYING, ASSESSING AND TREATING PATIENTS IN CANCER THERAPY | |
| EP1553912A4 (en) | COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT | |
| EP1656359A4 (en) | MACROCYCLIC BETA-SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| EP1771201A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-RELATED DISEASE | |
| IL229124A0 (en) | Inhibitors with a mutant form of kit | |
| MY133332A (en) | Pyrrolidone derivatives as maob inhibitors | |
| NO20053855L (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
| NO20065117L (no) | Sammensetning omfattende en JNK inhibitor og syklosporin. | |
| AU2003231252A1 (en) | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease | |
| MA27500A1 (fr) | Prevention et traitement de la maladie d'alzheimer | |
| MXPA05009986A (es) | Tratamiento de la enfermedad de alzheimer. | |
| WO2002039122A3 (en) | Methods for the identification and the treatment of cardiovascular disease | |
| EP1488808A4 (en) | Remedies for glomerular diseases | |
| ATE423102T1 (de) | 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer | |
| WO2004028456A3 (en) | Method and composition for treating neurodegenerative disorders | |
| TW200612900A (en) | The use of therapeutic and preventive action of l-3-n-butylphthalide on dementia, involving alzheimer's disease and vascular dementia | |
| DE60126504D1 (de) | Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa |